Treatment patterns of patients with neuromyelitis optica spectrum disorder switched to inebilizumab in Japan: a claims-based retrospective study
In Japan, several biological agents with distinct mechanisms of action are available for the prevention of relapse in neuromyelitis optica spectrum disorder (NMOSD), including the B cell-depleting agent inebilizumab. Understanding the management of transitions between these agents is crucial for exploring safe sw...